Login
$RNAC
$6.10 +$0.02 (0.33%) Pre-market

$RNAC SEC Filings

Filed On Filing
06 Nov 2026 SCHEDULE 13G/A
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) advances towards data readout expected in 1Q27 and biologics license application (BLA) filing planned for mid-2027

29 Sep 2026 8-K: Regulation FD Disclosure; Other Events

Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis

13 Aug 2026 SCHEDULE 13G
06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027

22 Jul 2026 SCHEDULE 13G/A
17 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 12, 2026, Cartesian Therapeutics, Inc. (the “Company”) held the 2026 Annual Meeting of Stockholders (the “Annual Meeting”). A total of 24,151,536 shares of the Company’s common stock, par value $0.0001 per share (the “common stoc...

09 Jun 2026 144
09 Jun 2026 8-K: Regulation FD Disclosure

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

02 Jun 2026 144
26 May 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +3 more

This LOAN AND SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of May 22, 2026 (the “Closing Date”) is entered into among CARTESIAN THERAPEUTICS, INC., a Delaware ...

06 May 2026 SCHEDULE 13G/A
30 Apr 2026 S-8
30 Apr 2026 10-Q
30 Apr 2026 8-K: Results of Operations and Financial Condition

Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis

28 Apr 2026 Proxy statement: annual meeting on June 12, 2026

CEO pay $4.3M, down 41% · say-on-pay vote

28 Apr 2026 DEFA14A
06 Apr 2026 Form 4: Hoge Elizabeth, 10% owner and 1 other

Received 758,001 shares by exercise or conversion

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support